completed

We studied the unclear question whether blood pressure (BP) lowering reduces cardiovascular disease (CVD) in elderly individuals with systolic BP <160 mm Hg.

The APOLLO study provided new information regarding the role of aliskiren (with additional therapy with a diuretic or a CCB) in elderly individuals with SBP 130 to 159 mmHg (who may already be receiving BP lowering drugs and other preventive strategies that their physicians believe are indicated) in preventing major CV events, and on global measures of physical, executive and cognitive function.

It used a 2 X 2 factorial design involving 11,000 elderly individuals followed for an average duration of five years. In May 2012 it was decided to prematurely close the APOLLO trial by the sponsor.

Study Type

Interventional - Drug

Study Design

Randomized, multicenter, double 2X2 factorial design

NO. of Countries

17

NO. of Sites

145

NO. of Participants

1759

Study Period

2011-2012

Sponsor

Novartis

Novartis

Back To Top